Xenon Pharmaceuticals Inc [NASDAQ: XENE] plunged by -$6.25 during the normal trading session on while it closed the day at $29.60.
Xenon Pharmaceuticals Inc stock has also loss -15.86% of its value over the past 7 days. However, XENE stock has declined by -22.90% in the 3 months of the year. Over the past six months meanwhile, it has lost -35.29% and lost -24.49% year-on date.
The market cap for XENE stock reached $2.27 billion, with 76.59 million shares outstanding and 74.34 million shares in the current float. Compared to the average trading volume of 732.64K shares, XENE reached a trading volume of 6758657 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Xenon Pharmaceuticals Inc [XENE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XENE shares is $55.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XENE stock is a recommendation set at 1.06. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Xenon Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 07, 2025. While these analysts kept the previous recommendation, Deutsche Bank raised their target price to Buy. The new note on the price target was released on February 11, 2025, representing the official price target for Xenon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $50, while Raymond James analysts kept a Outperform rating on XENE stock.
The Average True Range (ATR) for Xenon Pharmaceuticals Inc is set at 2.20, with the Price to Sales ratio for XENE stock in the period of the last 12 months amounting to 302.29. The Price to Book ratio for the last quarter was 3.22, with the Price to Cash per share for the same quarter was set at 7.18.
XENE stock trade performance evaluation
Xenon Pharmaceuticals Inc [XENE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.86. With this latest performance, XENE shares dropped by -5.73% in over the last four-week period, additionally sinking by -35.29% over the last 6 months – not to mention a drop of -30.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XENE stock in for the last two-week period is set at 31.36, with the RSI for the last a single of trading hit 23.47, and the three-weeks RSI is set at 35.89 for Xenon Pharmaceuticals Inc [XENE]. The present Moving Average for the last 50 days of trading for this stock 34.72, while it was recorded at 34.27 for the last single week of trading, and 39.01 for the last 200 days.
Xenon Pharmaceuticals Inc [XENE]: An insightful look at the core fundamentals
Xenon Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.66 and a Current Ratio set at 17.66.
Earnings per share (EPS) analysis for Xenon Pharmaceuticals Inc [XENE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for XENE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Xenon Pharmaceuticals Inc go to -13.46%.
Xenon Pharmaceuticals Inc [XENE]: Institutional Ownership
There are presently around $104.67%, or 104.94%% of XENE stock, in the hands of institutional investors. The top three institutional holders of XENE stocks are: FMR LLC with ownership of 6.77 million shares, which is approximately 8.7139%. AVORO CAPITAL ADVISORS LLC, holding 5.67 million shares of the stock with an approximate value of $$220.94 million in XENE stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $$172.32 million in XENE stock with ownership which is approximately 5.69%.
